PRESCIENT THERAPEUTICS LIMITED ASX ANNOUNCEMENT
1 September 2015
The Company Announcements Platform
ASX Limited
By E-lodgement
Professor Sebti has been ranked alongside Nobel laureate Dr David Baltimore on the internationally regarded list, which is compiled by patent analytics firm IP Checkups following examination of 2014's most active scientists for patenting
Scientists are included on the list following examination of each researcher's most-cited patent from the previous five years and their 'H index', which is a score based on the impact of published work.
As well as overseeing Prescient's oncology programs, Professor Sebti is the Manuel and Adeline Garcia Endowed Professor and Chair, Department of Drug Discovery, at the Moffitt Cancer Center in Florida; a National Cancer Institute-designated comprehensive cancer center, and one of the largest cancer centers in the US.
Professor Sebti was also elected a Fellow of the National Academy of Inventors in December 2014, a select group of 414 distinguished innovators acknowledged for their contribution to patents issued by the U.S. Patent and Trademark Office.
Prescient Therapeutics Managing Director Dr Rob Crombie said, "We are privileged to have such a distinguished scientist as Professor Sebti as part of our team. He has done seminal work in targeting Ras, AKT and other key cancer pathways and this distinction recognizes his important contributions in these areas."
"Furthermore, the fact that Professor Sebti's work is so frequently cited also demonstrates globally the relevance and importance of our strategic approach to targeting the AKT and Ras pathways to combat cancer."
The link to Bioentrepreneur Data in Nature Biotechnology Journal can be found at:
http://www.nature.com/bioent/2015/150801/fig_tab/bioe.2015.9_T1.html
ASX ANNOUNCEMENT
About Prescient Therapeutics
Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. Department of Defense and U.S. National Cancer Institute. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.
Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways downstream of Ras, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.
Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company
Transgene for use in two immunotherapeutic products.
Further Inquiries: | ||
Dr Robert Crombie | Paul Hopper | Rudi Michaelson |
Managing Director | Executive Director | Monsoon Communications |
+61 439 361 331 | +61 406 671 515 | +61 (0) 3 9620 3333 |
|
distributed by
|
